Market Overview

Tesaro Shares Tumble After Disappointing Data Results

Share:
Related TSRO
Benzinga Pro's 5 Stocks To Watch Today
Benzinga's Top Upgrades, Downgrades For November 15, 2017
TESARO updates U.S. Varubi label after reports of serious hypersensitivity reactions; shares down 4% premarket (Seeking Alpha)

Shares of Tesaro (NASDAQ: TSRO) dropped as much as 32.19% to $28.52 following the announcement that data from two trials showed that rolapitant for chemotherapy induced nausea and vomiting (CINV) missed secondary endpoints.

BMO Capital Markets analyst Jim Birchenough reported that investors had expected Tesaro's rolapitant to differentiate itself from other treatments for CINV based on nausea benefit which didn't reach statistical significance. Birchenough added that a better dosing schedule and the absence of reactions may not be enough to differentiate from Merck's Emend.

Tesaro closed at $37.70 on Friday.

Latest Ratings for TSRO

DateFirmActionFromTo
Nov 2017Leerink SwannUpgradesMarket PerformOutperform
Nov 2017Morgan StanleyMaintainsOverweight
Oct 2017BarclaysInitiates Coverage OnEqual-Weight

View More Analyst Ratings for TSRO
View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Jim BirchenoughAnalyst Color Analyst Ratings

 

Related Articles (TSRO)

View Comments and Join the Discussion!